---
document_datetime: 2023-09-21 18:11:49
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/protopy-epar-procedural-steps-taken-authorisation_en.pdf
document_name: protopy-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3750866
conversion_datetime: 2025-12-20 14:39:11.055669
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## I BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Fujisawa GmbH submitted on 28 July 2000 an application for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Protopy, through the centralised procedure. After agreement by the CPMP on 16 March 2000, this medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993 as amended.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

•

- During the meeting on 16-18 October 2001, the CPMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to Protopy on 18 October 2001.

Medicinal product no longer authorised Rapporteur: Dr. Mary Teeling Co-Rapporteur: Prof. Hans Winkler Dr. Patrick Salmon Prof. Heribert Pittner Scientific Advice: The applicant did not seek scientific advice at the CPMP. Licensing status: Protopy has been given a Marketing Authorisation in Japan on 16 June 1999, in USA on 8 December 2000 and in Canada on 25 June 2001. 2. Steps taken for the assessment of the product · The procedure started on 16 August 2000. · The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on  10 November  2000.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP members on 20 November 2000. · During the  meeting  on  12-14  December  2000,  the  CPMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the company on 15 December 2000. · The applicant submitted the responses to the CPMP consolidated List of Questions on 12 June 2001. · The  Rapporteur  and Co-Rapporteur  circulated the response Assessment  Report  on  the company's responses to the List of Questions to all CPMP members on 15 August 2001. · During  the  CPMP  meeting  on  18-20  September  2001,  the  CPMP  agreed  on  a  List  of Outstanding Issues. · Written explanations were provided by the applicant on 1 October 2001. · The  Rapporteur  and  Co-Rapporteur  circulated  a  Joint  Assessment  Report  on  the  company's responses to the List of Outstanding Issues to all CPMP members on 10 October 2001. During the CPMP meeting on 16-18 October 2001, outstanding issues were addressed by the applicant during a hearing before the CPMP.